CITARINOSTAT

WO 2016200930, New patent, Citarinostat, Acetylon Pharmaceuticals Inc

WO 2016200930, New patent, Citarinostat, Acetylon Pharmaceuticals Inc citarinostat Acetylon Pharmaceuticals Inc (WO2016200930) METHODS OF MAKING PROTEIN DEACETYLASE INHIBITORS (I) Compound (I) is disclosed in U.S. Patent No. 8,148,526 as an HDAC inhibitor. Example 2 of U.S. Patent Application Publication No. 2015/0099744 discloses a synthesis of compound (I). As detailed herein in Example 3, this …

Citarinostat Treatment of Hematological Malignancies, Molecular Formula, C24-H26-Cl-N5-O3, Molecular Weight, 467.9544, RN: 1316215-12-9 UNII: 441P620G3P 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide 5-Pyrimidinecarboxamide, 2-((2-chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)- ACY-241; HDAC-IN-2 Histone deacetylase-6 inhibitor Acute myelogenous leukemia; Cancer; Mantle cell lymphoma; Multiple myeloma Mechanism of ActionHDAC6 protein inhibitors Highest Development Phases Phase IIMultiple myeloma Phase IMalignant melanoma; Non-small cell lung cancer; Solid tumours Most Recent Events 12 …